Skip to main content

Advertisement

SpringerLink
Log in

Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To determine the frequency of anticyclic citrullinated peptide (CCP) antibodies in a cohort of psoriatic arthritis (PsA) patients and to compare clinical, serological and radiological characteristics between PsA patients with and without anti-CCP antibodies. Patients with PsA, according to classification criteria for PsA, were consecutively recruited from an outpatient rheumatology clinic. Demographic and clinical data were collected in all cases. Serum samples from all patients were analyzed for rheumatoid factor and anti-CCP antibodies. Radiographs of hands and feet were obtained and the presence of erosions was recorded. The study included 81 patients; 43 (53 %) were men, with a median age of 45.7 years (interquartile range (IQR) 39–72) and median disease duration of 9.4 years (IQR 2–14). Anti-CCP antibodies were found in 11 patients (13.5 %), median titer 174.9 U/ml. Polyarticular involvement (72.7 vs. 17.1 %), frequency of erosive disease (72.7 vs. 37.1 %) and use of tumor necrosis factor-α inhibitors (54.5 vs. 28.5 %) were significantly higher in PsA patients with anti-CCP positivity. Anti-CCP negative PsA patients had predominantly more oligoarticular (62.8 vs. 27.2 %) and nail (81.4 vs. 36.3 %) involvement. Presence of enthesitis, dactylitis and Psoriasis Area Severity Index scores were similar in both groups. Anti-CCP antibodies were found in a subset of PsA patients, and their presence was associated with more severe disease phenotype. Further studies in a larger population are needed to define the role of anti-CCP as a biomarker of erosive disease in PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moll J, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78

    Article  CAS  PubMed  Google Scholar 

  2. Marsal S, Armadans-Gil L, Martínez M et al (1999) Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 38:332–337

    Article  CAS  Google Scholar 

  3. McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 42:778–783

    Article  CAS  Google Scholar 

  4. Schellekens GA, Visser H, De Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163

    Article  CAS  PubMed  Google Scholar 

  5. Zendman AJ, Vossenaar ER, Van Venrooij W (2004) Autoantibodies to citrullinated (poly) peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 37:295–299

    Article  CAS  PubMed  Google Scholar 

  6. Gottenberg JE, Mignot S, Nicaise-Rolland P et al (2005) Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis 64:114–117

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Polimeni M, Feniman D, Skare TS et al (2012) Anti-cyclic citrullinated peptide in scleroderma patients. Clin Rheumatol 31(5):877–880

    Article  CAS  PubMed  Google Scholar 

  8. Cho SB, Lee JH, Ahn KJ et al (2012) Anti-cyclic citrullinated peptide antibodies and joint involvement in Behcet’s disease. Yonsei Med J 53(4):759–764

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Singh U, Singh S, Singh NK et al (2011) Anticyclic citrullinated peptide autoantibodies in systemic lupus erythematosus. Rheumatol Int 31(6):765–767

    Article  CAS  PubMed  Google Scholar 

  10. Kakumanu P, Sobel E, Narain S et al (2009) Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 36(12):2682–2690

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Qing YF, Zhang QB, Zhou JG et al (2009) The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus 8:713–717

    Article  Google Scholar 

  12. Chan MT, Owen P, Dunphy J et al (2008) Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 35:77–83

    PubMed  Google Scholar 

  13. Korendowych E, Owen P, Ravindran J et al (2005) The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology 44:1056–1060

    Article  CAS  PubMed  Google Scholar 

  14. Bogliolo L, Alpini C, Caporali R et al (2005) Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32:511–515

    CAS  PubMed  Google Scholar 

  15. Vander Cruyssen B, Hoffman I, Zmierczak H et al (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64:1145–1149

    Article  CAS  PubMed  Google Scholar 

  16. Inanc N, Dalkilic E, Kamali S et al (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17–23

    Article  CAS  PubMed  Google Scholar 

  17. Alenius GM, Berglin E, Rantapää Dahlqvist S (2006) Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 65:398–400

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Candia L, Marquez J, Gonzalez C et al (2006) Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol 12:226–229

    Article  PubMed  Google Scholar 

  19. Pasquetti P, Morozzi G, Galeazzi M (2009) Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology 48:315–316

    Article  CAS  PubMed  Google Scholar 

  20. Maejima H, Aki R, Watarai A et al (2010) Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients. J Dermatol 37:339–345

    Article  PubMed  Google Scholar 

  21. Taylor WJ, Gladman DD, Helliwell PS et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673

    Article  PubMed  Google Scholar 

  22. Helliwell P, Marchesoni A, Peters M et al (1991) A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 30:339–345

    Article  CAS  PubMed  Google Scholar 

  23. Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227

    Article  CAS  PubMed  Google Scholar 

  24. McGonagle D, Conaghan P, Emery P (1999) Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 42:1080–1086

    Article  CAS  PubMed  Google Scholar 

  25. Gladman D, Schukett R, Russell ML et al (1987) Psoriatic arthritis: clinical efficacy and laboratory analysis of 220 patients. Q J Med 62:127–141

    CAS  PubMed  Google Scholar 

  26. Yang DH, Tu CC, Wang SC et al. (2013) Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease. Rheumatol Int. doi:10.1007/s00296-013-2926-6

    PubMed Central  Google Scholar 

  27. Caspi D, Anouk M, Golan I et al (2006) Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Arthritis Care Res 55:53–56

    Article  CAS  Google Scholar 

  28. Vossenaar ER, Smeets T, Kraan M et al (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50:3485–3494

    Article  CAS  PubMed  Google Scholar 

  29. Kinloch A, Lundberg K, Wait R et al (2008) Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 58:2287–2295

    Article  CAS  PubMed  Google Scholar 

  30. Spadaro A, Riccieri R, Scrivo C et al (2007) Anti-cyclic citrullinated peptide antibody determination in synovial fluid of psoriatic arthritis. Clin Exp Rheumatol 25:599–604

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. LSU Health Sciences Center, New Orleans, LA, USA

    Rodolfo Perez-Alamino, Ignacio Garcia-Valladares, Raquel Cuchacovich & Luis R. Espinoza

  2. Department of Rheumatology, National University of Colombia, Bogotá, Colombia

    Antonio Iglesias-Gamarra

  3. Section of Rheumatology, Department of Internal Medicine, LSU Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA, 70112-2822, USA

    Rodolfo Perez-Alamino, Ignacio Garcia-Valladares, Raquel Cuchacovich & Luis R. Espinoza

Authors
  1. Rodolfo Perez-Alamino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ignacio Garcia-Valladares
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raquel Cuchacovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Iglesias-Gamarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luis R. Espinoza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rodolfo Perez-Alamino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perez-Alamino, R., Garcia-Valladares, I., Cuchacovich, R. et al. Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?. Rheumatol Int 34, 1211–1216 (2014). https://doi.org/10.1007/s00296-014-2956-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-2956-8

Keywords

Search

Navigation